<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981316</url>
  </required_header>
  <id_info>
    <org_study_id>15-008828</org_study_id>
    <nct_id>NCT02981316</nct_id>
  </id_info>
  <brief_title>Treatment of Recurrent Clostridium Difficile Infection With RBX7455</brief_title>
  <official_title>Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rebiotix Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of RBX7455 for the
      treatment of recurrent CDI in subjects who have had at least one recurrence after a primary
      episode (i.e., at least two episodes) and have completed at least two rounds of
      standard-of-care oral antibiotic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence of Clostridium Difficile Infection (CDI)</measure>
    <time_frame>approximately 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing adverse events</measure>
    <time_frame>approximately 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>RBX7455 Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 days of 4 capsules twice daily RBX7455 for 10 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBX7455 Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 days of 4 capsules twice daily RBX7455 for 10 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBX7455 Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 days of 2 capsules twice daily RBX7455 for 10 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBX7455 Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 days of 1 capsule twice daily RBX7455 for 10 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RBX7455</intervention_name>
    <description>Microbiota capsule(s) given twice daily in the morning, and in the evening.</description>
    <arm_group_label>RBX7455 Group A</arm_group_label>
    <arm_group_label>RBX7455 Group B</arm_group_label>
    <arm_group_label>RBX7455 Group C</arm_group_label>
    <arm_group_label>RBX7455 Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. ≥ 18 years old.

          2. Medical record documentation of recurrent CDI, defined as at least one recurrence
             after a primary episode and has completed at least two rounds of standard-of-care oral
             antibiotic therapy. Study subjects will have their diarrhea resolved, i.e., would be
             having less than 3 watery bowel movements at the time of study enrollment for 48 hours
             or more.

          3. A positive stool test for the presence of C. difficile within 30 days prior to
             enrollment and standard C. difficile treatment.

          4. Willing and able to swallow capsules.

          5. Agrees to abstain from non-dietary probiotics for the duration of the study.

          6. Agrees to abstain from vancomycin, metronidazole, fidaxomicin, rifaximin, nitazoxanide
             and IVIG for the duration of the study unless prescribed to treat recurrent CDI.

          7. Agrees to stop proton pump inhibitors or H2 blocker medications.

          8. Agrees to practice a form of effective contraception during study participation.

          9. Has a negative urine pregnancy test at the time of enrollment (females of
             child-bearing potential only).

         10. Willing and able to provide informed consent and HIPAA authorization.

         11. Willing and able to complete the required Subject Diary.

         12. Willing and able to meet all study requirements, including attending all assessment
             visits and phone calls.

        Exclusion criteria:

          1. A known history of continued CDI diarrhea, despite being on a course of antibiotics
             prescribed for CDI treatment.

          2. Requires continuous antibiotic therapy for a condition other than CDI.

          3. Previous fecal transplant.

          4. Previous treatment with RBX2660.

          5. Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's
             disease, or microscopic colitis.

          6. Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.

          7. History of chronic diarrhea.

          8. History of celiac disease.

          9. Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.

         10. Unable to stop proton pump inhibitors or H2 blocker medications.

         11. Colostomy.

         12. Intra-abdominal surgery within the last 60 days.

         13. Evidence of active, severe colitis.

         14. History of short gut syndrome.

         15. Requires the regular use of medications to manage bowel hypermotility.

         16. Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).

         17. Planned surgery requiring perioperative antibiotics within 3 months of study
             enrollment.

         18. Life expectancy of &lt; 6 months.

         19. Compromised immune system (e.g., HIV infection; AIDS-defining diagnosis or CD4
             &lt;200/mm3; inherited/primary immune disorders; immunodeficient or immunosuppressed due
             to a medical condition or medication; current or recent (&lt; 90 days) treatment with
             chemotherapy; or current or recent (&lt; 90 days) treatment with immunosuppressant
             medications.

         20. Taking systemic steroids (≥ 20 mg a day or prednisone-equivalent) or is expected to be
             on steroids after enrollment through 8 weeks after completing the assigned study
             treatment.

         21. An absolute neutrophil count of &lt;1000 cells/µL.

         22. Known or suspected current (&lt; 90 days) illicit drug use. Note: marijuana use is
             allowed.

         23. Pregnant, breastfeeding, or intends to become pregnant during study participation.

         24. Participating in a clinical trial of another investigational product (drug, device or
             other) and has not completed the required follow-up period.

         25. Subject, in the opinion of the investigator, for whatever reason, should be excluded
             from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahil Khanna</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renee Weatherly, R.N.</last_name>
    <phone>507-284-9709</phone>
    <email>weatherly.renee@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Weatherly</last_name>
      <phone>507-284-9709</phone>
      <email>weatherly.renee@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Kammer</last_name>
      <phone>507-538-1827</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sahil Khanna</investigator_full_name>
    <investigator_title>M.B.B.S.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

